tbuckley/cabot-search huggingface dataset:
Inducible IκB Kinase/IκB Kinase ε Expression Is Induced by CK2 and Promotes Aberrant Nuclear Factor-κB Activation in Breast Cancer Cells
Authors: Sean F. Eddy, Shangqin Guo, Elizabeth G. Demicco, Raphaëlle Romieu-Mourez, Esther Landesman-Bollag, David C. Seldin, Gail E. Sonenshein
Journal: Cancer Research (2005)

Abstract Aberrant activation of nuclear factor-κB (NF-κB) transcription factors has been implicated in the pathogenesis of breast cancer. We previously showed elevated activity of IκB kinase α (IKKα), IKKβ, and protein kinase CK2 in primary human breast cancer specimens and cultured cells. A novel inducible IKK protein termed IKK-i/IKKε has been characterized as a potential NF-κB activator. Here, we provide evidence that implicates IKK-i/IKKε in the pathogenesis of breast cancer. We show IKK-i/IKKε expression in primary human breast cancer specimens and carcinogen-induced mouse mammary tumors. Multiple breast cancer cell lines showed higher levels of IKK-i/IKKε and kinase activity compared with untransformed MCF-10F breast epithelial cells. Interestingly, IKK-i/IKKε expression correlated with CK2α expression in mammary glands and breast tumors derived from MMTV-CK2α transgenic mice. Ectopic CK2 expression in untransformed cells led to increased IKK-i/IKKε mRNA and protein levels. Inhibition of CK2α via the pharmacologic inhibitor apigenin or upon transfection of a CK2 kinase-inactive subunit reduced IKK-i/IKKε levels. Expression of a kinase-inactive IKK-i/IKKε mutant in breast cancer cells reduced NF-κB activity as judged by transfection assays of reporters driven either by NF-κB elements or the promoters of two NF-κB target genes, cyclin D1 and relB. Importantly, the kinase-inactive IKK-i/IKKε mutant reduced the endogenous levels of these genes as well as the ability of breast cancer cells to grow in soft agar or form invasive colonies in Matrigel. Thus, CK2 induces functional IKK-i/IKKε, which is an important mediator of the activation of NF-κB that plays a critical role in the pathogenesis of breast cancer. (Cancer Res 2005; 65(24): 11375-83)
Lifestyle effect on total IgE
Authors: T. Shirakawa, K. Morimoto
Journal: Allergy (1991)

Recent studies have demonstrated an increasing number of cases of allergy in economically developed societies. Many of these allergic reactions are mediated by IgE antibodies whose levels are under genetic control. However, this large increase of allergy prevalence cannot be explained by genetic mutations; comprehensive lifestyles may also play roles in determining total IgE levels. Total IgE levels were determined from scrum samples taken from 706 hard metal workers who responded lo a questionnaire including 17 items related to physical and mental health practices. Five actors tending to normalize IgE upward and three tending to normalize IgE downward when we keep good lifestyles were extracted using MANOVA analysis. We therefore constructed a Health Practice Index in Allergic reactions (HPIA); eight physical and mental health practices were significantly ( P &lt; 0.05) associated with cumulative elevations or suppressions of total IgE levels when sex, age and environmental factors were controlled for. Multivariate analyses demonstrated a dramatic synergism (Relative Risk &gt; 2.0, P &lt; 0.05) of unhealthy lifestyles determining a bipolar high risk for elevated or suppressed IgE levels which in turn may result in allergic diseases or immuno‐suppression. Maintenance of healthy lifestyles may prove beneficial for reducing the prevalence of allergic disorders.
Logistic regression analysis of values of skin testing and IgE antibodies to predict actual clinical allergy to shrimp in adult subjects
Authors: J. Rodríguez, P. Poza-Guedes, J.F. Crespo, P. Daroca, A. Gómez-Cámara, M.L. Somoza, R. Vives
Journal: Journal of Allergy and Clinical Immunology (2003)
Nintedanib reduced decline in FVC in idiopathic pulmonary fibrosis
Authors: Fiona Lake
Journal: Annals of Internal Medicine (2014)

ACP Journal Club21 October 2014Nintedanib reduced decline in FVC in idiopathic pulmonary fibrosisFiona Lake, MDFiona Lake, MDUniversity of Western Australia and Sir Charles Gairdner Hospital, Perth, Western Australia, Australia (F.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-161-8-201410210-02005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationRicheldi L, du Bois RM, Raghu G, et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82. https://pubmed.ncbi.nlm.nih.gov/24836310Clinical Impact RatingsPulmonology: References1 Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824. [PMID: 21471066] Google Scholar2 Taniguchi H, Ebina M, Kondoh Y, et al; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821-9. [PMID: 19996196] Google Scholar3 Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-9. [PMID: 21571362] Google Scholar4 Wells AU, Kokosi M, Karagiannis K. Treatment strategies for idiopathic interstitial pneumonias. Curr Opin Pulm Med. 2014;20:442-8. [PMID: 25032814] Google Scholar Author, Article, and Disclosure InformationAuthors: Fiona Lake, MDAffiliations: University of Western Australia and Sir Charles Gairdner Hospital, Perth, Western Australia, Australia (F.L.)This article was published at Annals.org on 7 October 2014. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPirfenidone reduced disease progression in idiopathic pulmonary fibrosis Fiona Lake Metrics 21 October 2014Volume 161, Issue 8Page: JC5KeywordsDrugsEnzymesForced vital capacityHazard ratioInterstitial lung diseasesLiverPatientsQuality of lifeQuestionnairesSafety ePublished: 21 October 2014 Issue Published: 21 October 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The HLA-DPB1∗0301 marker might predict the requirement for leukotriene receptor antagonist in patients with aspirin-intolerant asthma☆
Authors: Hae-Sim Park, Seung-Hyun Kim, Anthony P. Sampson, Kyung-Wha Lee, Choon-Sik Park
Journal: Journal of Allergy and Clinical Immunology (2004)
Abstract 647: Use of statin and risk of prostate cancer recurrence among patients who received radical prostatectomy
Authors: Chun R. Chao, Lanfang Xu, Lauren P. Wallner, Kimberly P. Porter, Steven Jacobsen, Stephen G. Williams
Journal: Cancer Research (2012)

Abstract Background: HMG-CoA reductase inhibitors (“statins”) have shown broad-spectrum anti-cancer properties in laboratory studies. In epidemiologic studies, statin use has been linked to reduced risk of advanced prostate cancer (PCa). We investigated whether statin use is associated with reduced risk of recurrence in PCa patients who received radical prostatectomy. Methods: All men with incident PCa diagnosed between 2004-2005 who subsequently underwent radical prostatectomy in Kaiser Permanente Southern California (KPSC) health plan were identified using KPSC's accredited cancer registry. Exclusion criteria included &amp;lt;24 months prior KPSC membership, use of neoadjuvant therapy, and stage 4 disease. Subjects were followed for 5 years after prostatectomy for: (1) Biochemical recurrence, defined as a single PSA measurement &amp;gt;0.2 ng/ml; and (2) clinical disease progression, defined as diagnosis of metastatic disease (identified using ICD-9 codes) or PCa-related death (i.e., PCa as primary cause of death). Information on statin use, demographics, co-morbid conditions, pathoclinical prognostic factors, e.g., stage and Gleason score, and outcomes were obtained from cancer registry and electronic medical records. The effects of statin use prior to and after prostatectomy were both examined using bivariate and multivariable Cox models, adjusting for known prognostic factors. For post-operative statin exposure, a time-dependent Cox model was used. Results: A total of 1192 men were included; 38% had pre-operative and 55% had post-operative statin use. Neither pre- nor post-operative statin use was associated with risk of any outcome, as there was no evidence of a clear dose-response relationship (Table). Conclusion: These data suggest that despite statin's protective effect in developing PCa, statin use may not prevent PCa progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 647. doi:1538-7445.AM2012-647
Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments.
Authors: Y Terada, K Tomita, H Nonoguchi, F Marumo
Journal: Journal of Clinical Investigation (1992)

Stimulation of the release of nitric oxide (NO) in the kidney has been shown to result in renal hemodynamic changes and natriuresis. NO is a potent stimulator of soluble guanylate cyclase, leading to an increase of cyclic GMP. The precise localization of NO synthase and soluble guanylate cyclase in the renal structure is not known. In this study, the microlocalization of mRNAs coding for constitutive NO synthase and soluble guanylate cyclase was carried out in the rat kidney, using an assay of reverse transcription and polymerase chain reaction in individual microdissected renal tubule segments along the nephron, glomeruli, vasa recta bundle, and arcuate arteries. A large signal for constitutive NO synthase was detected in inner medullary collecting duct. Small signals were detected in inner medullary thin limb, cortical collecting duct, outer medullary collecting duct, glomerulus, vasa recta, and arcuate artery. Soluble guanylate cyclase mRNA is expressed largely in glomerulus, proximal convoluted tubule, proximal straight tubule, and cortical collecting duct, and in small amounts in medullary thick ascending limb, inner medullary thin limb, outer medullary collecting duct, inner medullary collecting duct, and the vascular system. Our data demonstrate that NO can be produced locally in the kidney, and that soluble guanylate cyclase is widely distributed in glomerulus, renal tubules, and the vascular system.
Violence and Delusions: Data From the MacArthur Violence Risk Assessment Study
Authors: Paul S. Appelbaum, Pamela Clark Robbins, John Monahan
Journal: American Journal of Psychiatry (2000)

OBJECTIVE: Previous work has suggested that delusions are associated with a higher risk of violence, particularly delusions in which patients believe that people are seeking to harm them or that outside forces are controlling their minds (denoted as "threat/control override" delusions). This study explores the relationship between delusions and violence among patients recently discharged from acute psychiatric hospitalization. METHOD: Data were drawn from the MacArthur Violence Risk Assessment Study, a study of violence in the community that followed 1,136 recently discharged psychiatric patients for 1 year. Interviews at discharge and at five 10-week intervals gathered clinical, historical, situational, and dispositional information, including the presence and nature of delusional thoughts. Violence was ascertained from reports of subjects, collateral informants, and official records. RESULTS: Neither delusions in general nor threat/control override delusions in particular were associated with a higher risk of violent behavior. Comparisons with prior studies suggest that reliance on subject self-reports of delusional symptoms may result in mislabeling as delusions other phenomena that can contribute to violence. CONCLUSIONS: Although delusions can precipitate violence in individual cases, these data suggest that they do not increase the overall risk of violence in persons with mental illness in the year after discharge from hospitalization.
Facial Dermatitis of Unknown Cause
Authors: William H. Kaufman
Journal: JAMA (1965)

AN UNUSUAL and remarkably consistent disorder of the face, differing in a number of ways from those with a similar distribution, was described in a preliminary report. 1   During the past four years, 62 white females, aged 11 to 74 years, were seen with an eruption characterized by intense, nonpruritic erythema, faint scaling, and, occasionally, discrete and confluent papules, with distribution to the nasolabial folds, upper lip, chin, nose, and, infrequently, the forehead and malar areas. Often, the regions immediately adjacent to the lips were spared, and consequently there was a relative pallor of the circumoral region.  The eruption characteristically was sudden in onset, remaining stationary after reaching a maximum spread in two or three days. Subjectively, there were few complaints. An occasional patient described mild itching or burning, but most sought relief from the cosmetic aspects of the disorder (Figure).  Duration of the disease before treatment varied from one
Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
Authors: C Schaab, F S Oppermann, M Klammer, H Pfeifer, A Tebbe, T Oellerich, J Krauter, M Levis, A E Perl, H Daub, B Steffen, K Godl, H Serve
Journal: Leukemia (2013)

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
ANSWER TO DR R. W. SUTTON.
Authors: Donald Maclean
Journal: JAMA (1884)

72 Lafayette Ave., Detroit Mich., November 18, 1884. <h3>To the Editor.—Dear Sir:</h3> In your issue of 15th inst., Dr. R. S. Sutton invites me to recall a fatal case of ovariotomy in my practice which occurred at Lansing, Mich., in January last, and of which he claims to have in his possession a certificate of death. In reply I must absolutely decline any such invitation, and must say to Dr. Sutton that any such certificate is either a gross blunder or a wicked forgery.<i>The simple fact is that I have never in my life performed ovariotomy at Lansing nor upon a Lansing patient any where at any time</i>. In the face of Dr. R. S. Sutton's repeated assaults upon my reputation for truth and veracity, I hope that I may be allowed to say here that if anything could exceed the grotesqueness of that gentleman's frantic efforts
Soluble CD40 Ligand Impairs the Function of Peripheral Blood Angiogenic Outgrowth Cells and Increases Neointimal Formation After Arterial Injury
Authors: Mihail Hristov, Denis Gümbel, Esther Lutgens, Alma Zernecke, Christian Weber
Journal: Circulation (2010)

Background— Recent work has revealed an essential involvement of soluble CD40 ligand (sCD40L) in inflammation and atherosclerosis. We investigated whether sCD40L functionally affects peripheral blood–derived angiogenic early outgrowth cells (EOCs) and neointimal remodeling after arterial injury. Methods and Results— Besides myeloid and endothelial markers, cultured human EOCs strongly expressed CD40 mRNA and protein. EOC adhesion to fibronectin, fibrinogen, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 under flow conditions, as well as their transmigration toward stromal cell–derived factor-1α, was dose-dependently reduced after preincubation with recombinant human sCD40L for 24 hours. Integrin expression was unaffected by sCD40L, implying that integrin adhesiveness was attenuated. Surface-immobilized CD40L supported much lower adhesion of EOCs than fibronectin. Treatment of EOCs with sCD40L increased superoxide anion production and decreased viability and proliferation. Notably, CD40 −/− mice displayed reduced neointima and improved re-endothelialization after carotid wire injury compared with wild-type mice, and therapeutic infusion of control EOCs but not EOCs pretreated with sCD40L attenuated neointimal growth after wire injury in nude mice. Furthermore, neointimal growth was more markedly diminished by infusion of spleen-derived CD40 −/− mouse EOCs than by that of wild-type EOCs. Preincubation of wild-type EOCs but not CD40 −/− EOCs with sCD40L before their infusion markedly aggravated neointimal formation. Treatment with sCD40L attenuated luminal incorporation of EOCs and accelerated neointimal progression. Conclusions— Endothelial dysfunction due to persistently elevated plasma levels of sCD40L may be attributable to an impairment of EOC function. Hence, in the context of arterial injury, therapeutic blockade of sCD40L may provide a novel strategy for accelerating endothelial regeneration and attenuating neointimal remodeling.
Sustainable business makes dollars and sense.
Authors: Scott Fields
Journal: Environmental Health Perspectives (2002)

The last decade has marked a radical change in the business of sustainability, say environmental activists and industrialists alike. On the wane are "greenwashing" campaigns in which corporations promote dubious environmental accomplishments to draw attention away from environmentally damaging practices. On the rise are corporate investments in sustainability programs, new types of environmental markets, and public demand for green products and investments. Once an afterthought, an annoyance, or a nonentity, sustainability is now often a focal point for businesses. No longer thought of as a business cost, environmentally benign practices are now viewed as a competitive advantage as companies seek to win both stockholders and customers.
Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation
Authors: Christopher S Garris, Linfeng Wu, Swati Acharya, Ahmet Arac, Victoria A Blaho, Yingxiang Huang, Byoung San Moon, Robert C Axtell, Peggy P Ho, Gary K Steinberg, David B Lewis, Raymond A Sobel, David K Han, Lawrence Steinman, Michael P Snyder, Timothy Hla, May H Han
Journal: Nature Immunology (2013)
The Place of Genetics in Medicine
Authors: CURT STERN
Journal: Annals of Internal Medicine (1971)

This convocation oration surveys a number of areas in human genetics that are relevant to medical practice. Among the topics dealt with are premendelian empirical findings on transmission of disease states and their later rational interpretation in terms of mendelian genes, genetic counseling, treatments of inborn errors of metabolism, amniocentesis and pregnancy termination, pharmacogenetics, and linkage studies of the genes in human chromosomes as tools in genetic prognosis. Ethical problems are dealt with, such as problems related to secrecy concerning genetic defects, therapeutic abortions, increases in the load of mutations in the human gene pool because of therapeutic successes, deliberate manipulation of genes at the biochemical level, and differential reproduction of genetically different population samples, as well as experimental embryological methods applied to humans, such as cloning.
A Systematic Plan for Firearms Law Reform
Authors: Katherine L. Record, Lawrence O. Gostin
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumor DNA Content in the Prognosis of Colorectal Carcinoma
Authors: William Kokal
Journal: JAMA (1986)

Tumor DNA content has been described as having prognostic significance in patients with colorectal carcinoma. It has been unclear, however, whether tumor ploidy as a prognostic factor is independent of various standard prognostic variables such as depth of invasion and lymph node involvement by the tumor. We retrospectively examined 77 patients who were diagnosed between 1974 and 1980 as having had resectable Dukes' stage A, B, or C colorectal carcinomas. The DNA content of each tumor was analyzed by flow cytometry on paraffin-embedded specimens. Both for aneuploid stage B tumors and for the entire group of aneuploid tumors, the disease-free and overall survival times of the patients were significantly shorter than those of patients with diploid colorectal carcinomas. Logistic regression analysis demonstrated that aneuploidy was an independent prognostic variable in predicting recurrent disease as well as death from the colorectal cancer. Tumor ploidy was, in fact, the single most important prognostic factor among all of the clinical and pathologic variables studied. Thus, the DNA content of colorectal carcinoma appears to play an important role in indicating the biologic aggressiveness of the disease. (<i>JAMA</i>1986;255:3123-3127)
Platelet-Derived Growth Factor-AB Limits the Extent of Myocardial Infarction in a Rat Model
Authors: Jay M. Edelberg, Seung H. Lee, Manmeen Kaur, Lilong Tang, Nikki M. Feirt, Samuel McCabe, Orville Bramwell, S. Chiu Wong, Mun K. Hong
Journal: Circulation (2002)

Background — Compared with younger patients, myocardial infarction in the elderly has been associated with less favorable clinical outcomes, which may be attributable to a decline in angiogenic capacity in the aging heart. Methods and Results — To test the hypothesis that the functional phenotype of cardiac microvascular endothelial cells is maintained partly by a cardiac myocyte platelet-derived growth factor (PDGF)-B–induced paracrine pathway, we conducted in vitro studies with murine cardiac cells. These studies demonstrated that unlike young endothelial cells, endothelial cells of the aging heart do not express PDGF-B when cultured in the presence of cardiac myocytes. The functional significance of this endothelial dysregulation was assessed with an ex vivo pinnal cardiac allograft model to demonstrate that senescent cardiac angiogenic activity was depressed (2 of 17 allografts were viable in 18-month-old mice versus 19 of 20 in 3-month-old mice; P &lt;0.01). PDGF-AB pretreatment specifically restored the viability of the cardiac allografts in the aging hosts (13 of 13 allografts were viable; P &lt;0.01 versus 18-month-old controls). Finally, in vivo studies in rat hearts demonstrated that pretreatment by intramyocardial delivery of PDGF-AB promotes angiogenesis and minimizes the extent of myocardial infarction in the aging hearts after coronary ligation (myocardial infarction size: 10.0±7.0% of left ventricular area in PDGF pretreatment [n=7] versus 17.6±5.6% in control [n=5] groups; P &lt;0.03). Conclusion — Aging hearts have impaired angiogenic function as a result of depressed PDGF-B production. Restoration of the dysregulated endothelial PDGF-mediated angiogenic pathway in the aging heart reverses the senescent impairment in cardioprotective angiogenic function and offers a foundation for developing novel therapies for cardiovascular disease in older individuals.